279 related articles for article (PubMed ID: 28008921)
1. Reprogramming the immunological microenvironment through radiation and targeting Axl.
Aguilera TA; Rafat M; Castellini L; Shehade H; Kariolis MS; Hui AB; Stehr H; von Eyben R; Jiang D; Ellies LG; Koong AC; Diehn M; Rankin EB; Graves EE; Giaccia AJ
Nat Commun; 2016 Dec; 7():13898. PubMed ID: 28008921
[TBL] [Abstract][Full Text] [Related]
2. Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
Boshuizen J; Pencheva N; Krijgsman O; Altimari DD; Castro PG; de Bruijn B; Ligtenberg MA; Gresnigt-Van den Heuvel E; Vredevoogd DW; Song JY; Visser N; Apriamashvili G; Janmaat ML; Plantinga TS; Franken P; Houtkamp M; Lingnau A; Jure-Kunkel M; Peeper DS
Cancer Res; 2021 Apr; 81(7):1775-1787. PubMed ID: 33531370
[TBL] [Abstract][Full Text] [Related]
3. Targeting GAS6/AXL signaling improves the response to immunotherapy by restoring the anti-immunogenic tumor microenvironment in gastric cancer.
Kim TH; Lee D; Oh HJ; Ham IH; Lee DM; Lee Y; Zhang Z; Ke D; Hur H
Life Sci; 2023 Dec; 335():122230. PubMed ID: 37952835
[TBL] [Abstract][Full Text] [Related]
4. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.
Engelsen AST; Lotsberg ML; Abou Khouzam R; Thiery JP; Lorens JB; Chouaib S; Terry S
Front Immunol; 2022; 13():869676. PubMed ID: 35572601
[TBL] [Abstract][Full Text] [Related]
6. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
Sadahiro H; Kang KD; Gibson JT; Minata M; Yu H; Shi J; Chhipa R; Chen Z; Lu S; Simoni Y; Furuta T; Sabit H; Zhang S; Bastola S; Yamaguchi S; Alsheikh H; Komarova S; Wang J; Kim SH; Hambardzumyan D; Lu X; Newell EW; DasGupta B; Nakada M; Lee LJ; Nabors B; Norian LA; Nakano I
Cancer Res; 2018 Jun; 78(11):3002-3013. PubMed ID: 29531161
[TBL] [Abstract][Full Text] [Related]
7. Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels.
Goyette MA; Elkholi IE; Apcher C; Kuasne H; Rothlin CV; Muller WJ; Richard DE; Park M; Gratton JP; Côté JF
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34266948
[TBL] [Abstract][Full Text] [Related]
8. AXL kinase as a novel target for cancer therapy.
Wu X; Liu X; Koul S; Lee CY; Zhang Z; Halmos B
Oncotarget; 2014 Oct; 5(20):9546-63. PubMed ID: 25337673
[TBL] [Abstract][Full Text] [Related]
9. TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.
Akalu YT; Rothlin CV; Ghosh S
Immunol Rev; 2017 Mar; 276(1):165-177. PubMed ID: 28258690
[TBL] [Abstract][Full Text] [Related]
10. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers.
Wei J; Sun H; Zhang A; Wu X; Li Y; Liu J; Duan Y; Xiao F; Wang H; Lv M; Wang L; Wu C
Cell Immunol; 2018 Sep; 331():49-58. PubMed ID: 29935762
[TBL] [Abstract][Full Text] [Related]
11. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
12. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
Linger RM; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DH; Lu X; Barón AE; Franklin WA; Merrick DT; Jedlicka P; DeRyckere D; Heasley LE; Graham DK
Oncogene; 2013 Jul; 32(29):3420-31. PubMed ID: 22890323
[TBL] [Abstract][Full Text] [Related]
13. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
[TBL] [Abstract][Full Text] [Related]
14. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.
Leconet W; Larbouret C; Chardès T; Thomas G; Neiveyans M; Busson M; Jarlier M; Radosevic-Robin N; Pugnière M; Bernex F; Penault-Llorca F; Pasquet JM; Pèlegrin A; Robert B
Oncogene; 2014 Nov; 33(47):5405-14. PubMed ID: 24240689
[TBL] [Abstract][Full Text] [Related]
15. An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo.
Subramanian M; Hayes CD; Thome JJ; Thorp E; Matsushima GK; Herz J; Farber DL; Liu K; Lakshmana M; Tabas I
J Clin Invest; 2014 Mar; 124(3):1296-308. PubMed ID: 24509082
[TBL] [Abstract][Full Text] [Related]
16. Axl acts as a tumor suppressor by regulating LIGHT expression in T lymphoma.
Lee EH; Kim EM; Ji KY; Park AR; Choi HR; Lee HY; Kim SM; Chung BY; Park CH; Choi HJ; Ko YH; Bai HW; Kang HS
Oncotarget; 2017 Mar; 8(13):20645-20655. PubMed ID: 28423548
[TBL] [Abstract][Full Text] [Related]
17. Giving AXL the axe: targeting AXL in human malignancy.
Gay CM; Balaji K; Byers LA
Br J Cancer; 2017 Feb; 116(4):415-423. PubMed ID: 28072762
[TBL] [Abstract][Full Text] [Related]
18. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma.
Yu H; Liu R; Ma B; Li X; Yen HY; Zhou Y; Krasnoperov V; Xia Z; Zhang X; Bove AM; Buscarini M; Parekh D; Gill IS; Liao Q; Tretiakova M; Quinn D; Zhao J; Gill PS
Br J Cancer; 2015 Aug; 113(4):616-25. PubMed ID: 26180925
[TBL] [Abstract][Full Text] [Related]
19. Mice lacking Axl and Mer tyrosine kinase receptors are susceptible to experimental autoimmune orchitis induction.
Li N; Liu Z; Zhang Y; Chen Q; Liu P; Cheng CY; Lee WM; Chen Y; Han D
Immunol Cell Biol; 2015 Mar; 93(3):311-20. PubMed ID: 25403570
[TBL] [Abstract][Full Text] [Related]
20. AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer.
Du W; Phinney NZ; Huang H; Wang Z; Westcott J; Toombs JE; Zhang Y; Beg MS; Wilkie TM; Lorens JB; Brekken RA
Mol Cancer Res; 2021 Aug; 19(8):1412-1421. PubMed ID: 33811159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
